Announcement on Voluntary Disclosure of Acceptance of the Clinical Trial Application for Chiglitazar Sodium Sustained-release Tablets

About this update from Shenzhen Chipscreen Biosciences Co. Ltd. Class A

Announcement on Voluntary Disclosure of Acceptance of the Clinical Trial Application for Chiglitazar Sodium Sustained-release Tablets The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Shenzhen Chipscreen Biosciences Co. Ltd. Class A